These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 11804273)

  • 21. HPV vaccine MedImmune/GlaxoSmithKline.
    Billich A
    Curr Opin Investig Drugs; 2003 Feb; 4(2):210-3. PubMed ID: 12669384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.
    Sheu BC; Chang WC; Lin HH; Chow SN; Huang SC
    J Obstet Gynaecol Res; 2007 Apr; 33(2):103-13. PubMed ID: 17441881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Technology evaluation: HspE7, StressGen Biotechnologies Corp.
    Hunt S
    Curr Opin Mol Ther; 2001 Aug; 3(4):413-7. PubMed ID: 11525566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer.
    Bellone S; Pecorelli S; Cannon MJ; Santin AD
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1473-86. PubMed ID: 17944571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventative and therapeutic vaccines for cervical cancer.
    Roden R; Wu TC
    Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV induced cervical carcinogenesis: molecular basis and vaccine development.
    Kaufmann AM; Backsch C; Schneider A; Dürst M
    Zentralbl Gynakol; 2002 Nov; 124(11):511-24. PubMed ID: 12796844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer.
    Branca M; Ciotti M; Santini D; Bonito LD; Benedetto A; Giorgi C; Paba P; Favalli C; Costa S; Agarossi A; Alderisio M; Syrjänen K;
    Am J Clin Pathol; 2004 Dec; 122(6):902-11. PubMed ID: 15539382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts.
    Lacey CJ; Thompson HS; Monteiro EF; O'Neill T; Davies ML; Holding FP; Fallon RE; Roberts JS
    J Infect Dis; 1999 Mar; 179(3):612-8. PubMed ID: 9952367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for an SV40 vaccine.
    Imperiale MJ; Pass HI; Sanda MG
    Semin Cancer Biol; 2001 Feb; 11(1):81-5. PubMed ID: 11243902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-cell tolerance.
    Wilcox RA; Chen L
    Front Biosci; 2002 Apr; 7():d853-71. PubMed ID: 11897572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Papillomavirus: biology and clinical implications for immunotherapy.
    Stanley M
    Mol Med Today; 1997 Jun; 3(6):239-40. PubMed ID: 9211412
    [No Abstract]   [Full Text] [Related]  

  • 34. Cantab failure shows need for wide portfolio.
    Fletcher L
    Nat Biotechnol; 2000 Dec; 18(12):1238. PubMed ID: 11101793
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of interferon treatment of cervical intraepithelial neoplasia.
    Coleman DV
    Acta Cytol; 1985; 29(2):192-3. PubMed ID: 3885665
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer vaccination. Politically incorrect viruses.
    Parham P
    Nature; 1994 Apr; 368(6471):495-6. PubMed ID: 8139680
    [No Abstract]   [Full Text] [Related]  

  • 37. Technology evaluation: T-cell activator, Xenova.
    Knutson KL
    Curr Opin Mol Ther; 2001 Dec; 3(6):585-8. PubMed ID: 11804273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
    Hibbitts S
    Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.